Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense? by Amodeo, V. et al.
1. Introduction
2. Materials and methods
3. Results
4. Discussion
5. Conclusion
Original Research
Effects of anti-miR-182 on
TSP-1 expression in human colon
cancer cells: there is a sense in
antisense?
Valeria Amodeo, Viviana Bazan, Daniele Fanale, Lavinia Insalaco,
Stefano Caruso, Giuseppe Cicero, Giuseppe Bronte, Christian Rolfo,
Daniele Santini & Antonio Russo†
†University of Palermo, Section of Medical Oncology, Department of Surgical, Oncological and
Stomatological Sciences, Palermo, Italy
Objective: miRNAs are attractive molecules for cancer treatment, including
colon rectal cancer (CRC).We investigate on themolecular mechanism bywhich
miR-182 could regulate thrombospondin-1 (TSP-1) expression, a protein down-
regulated in CRC and inversely correlatedwith tumor vascularity andmetastasis.
Background: MicroRNAs are small non-coding RNAs that regulate the expres-
sion of different genes, involved in cancer progression, angiogenesis and
metastasis. miR-182, over-expressed in colorectal cancer (CRC), has like predic-
tive target thrombospondin-1 (TSP-1), a protein inversely correlated with
tumor vascularity and metastasis that results downregulated in different types
of cancer including CRC.
Results: We found that TSP-1 increased after transfection with anti-miR-182
and we showed that miR-182 targets TSP-1 3¢UTR-mRNA in both cells. More-
over, we observed that anti-miR-182 did not induce significant variation of
Egr-1 expression, but affected the nuclear translocation and its binding on
tsp-1 promoter in HCT-116. Equally, Sp-1 was slightly increased as total
protein, rather we found a nuclear accumulation and its loading on the
TSP-1 promoter in HT-29 transfected with anti-miR-182.
Conclusion: Our data suggest that miR-182 targets the anti-angiogenic factor
TSP-1 and that anti-miR-182 determines an upregulation of TSP-1 expression
in colon cancer cells. Moreover, anti-miR-182 exerts a transcriptional regula-
tory mechanism of tsp-1 modulating Egr-1 and Sp-1 function. Anti-miR-182
could be used to restore TSP-1 expression in order to contrast angiogenic
and invasive events in CRC.
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1. Introduction
Colorectal cancer (CRC) is the second most frequent malignant disease [1] and the
second most common cause of cancer-related mortality in Europe [2]; 20 -- 25% of
patients have already metastasis after diagnosis [3]. Newest chemotherapeutics
agents, the so-called ‘targeted’ or ‘biological’ therapies, have improved survival in
patients with metastatic CRC, but having a relatively small effect on overall
survival [4-6]. For this reason, new therapeutic approaches are necessary to control
angiogenic spread. Angiogenesis is an important determinant of tumor progression.
Dysregulated expression of pro-angiogenic factors and angiogenic inhibitors nega-
tively influences the balance between capillary formation and regression, resulting
in new vessels formation from existing blood vessels and subsequent remodeling.
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MicroRNAs (miRNAs) are small non-coding RNAs
of ~ 20 -- 22 nucleotides in length that negatively regulate
gene expression in a variety of eukaryotic organisms [7]. miR-
NAs are known to regulate different cellular processes such as
proliferation, differentiation, apoptosis, cell metabolism [8,9].
Recently, several miRNAs were found to regulate angiogenic
processes [10] including pro-angiogenic, as VEGF [11,12], and
anti-angiogenic factors [13], as TSP-1, the first described
endogenous angiogenesis inhibitor. TSP-1 is a member of
calcium-binding extracellular proteins family [14]; it is a plate-
let- and cell-derived homotrimeric glycoprotein, secreted in a
wide range of tissues where it is bound to the extracellular
matrix [15]. Numerous in vitro and in vivo experiments have
been carried out in order to identify multiple mechanisms
by which TSP-1 inhibits angiogenesis. Three copies of the
thrombospondin type 1 repeat (TSR) [16] are essential to
inhibit tumor angiogenesis and growth.
An important mechanism through which TSP-1 regulates
angiogenesis is through interactions with the receptor
CD47, universally expressed by vascular and circulating blood
cells of land-dwelling vertebrates. High-affinity binding of
TSP-1 to CD47 occurs at two peptide motifs on the
carboxy-terminal domain [17]. TSP-1 at picomolar concentra-
tions activates CD47, inhibiting the pro-angiogenic nitric
oxide (NO)-stimulated activation of soluble guanylyl cyclase
(sGC) in endothelial cells, vascular smooth muscle cell
(VSMC), platelets and T cells [18-21]. This activity is lost in
CD47 null but not in CD36 null cells and is mimicked by
certain ligands of CD47 [22]. Ligation of CD36 also inhibits
sGC activation, but only at higher concentrations of
TSP-1 and only in cells that express CD47. TSP-1 also
enhanced VSMC proliferation by ligation of CD47 [23,24].
Pre-existing levels of TSP-1 in the arterial wall or blood
constantly limit NO-mediated vasodilation and blood flow
via CD47 [25]. In fact, healthy TSP-1 null mice showed a
greater increase in skeletal muscle blood flow in response to
NO within 5 min [26]. The direct inhibition of VSMC NO
signaling and indirect inhibition via limiting endothelial
NO synthesis are CD47-dependent targets that can control
vascular tone. Additional TSP-1 receptors are present on vas-
cular cells, some of which can oppose these CD47-dependent
signals if TSP-1 levels are sufficiently elevated [27].
VEGFA is an important driver of NO signaling via stimu-
lation of endothelial nitric oxide synthase (eNOS) [28] and
TSP-1 inhibits VEGF signaling via several mechanisms.
TSP-1 binds to VEGF and prevents VEGFR2 signaling either
by competing with extracellular VEGF for binding to cell
surface proteoglycans or by promoting VEGF clearance via
low-density lipoprotein receptor-related protein-1 (LRP1/
CD91) [29,30]. Second, TSP-1 binding to its receptor CD36
modulates VEGFR2 via a complex involving CD36, the
TSP-1 binding integrin a6b1 and VEGFR2 [31]. Third,
CD47 is a proximal binding partner of VEGFR2, and
TSP-1 binding to CD47 disrupts this complex and inhibits
VEGFR2 activation [32].
Through TSRs, TSP-1 binds CD36, b1 integrins and
TGF-b. Several lines of evidence indicate that anti-angiogenic
activity of TSP-1 is mostly mediated by the inhibition of
endothelial cell migration and by the induction of apoptosis
via interaction of TSP-1 with CD36 [33,34]. The interaction
of TSRs and b1 integrins inhibits the migration of endothelial
cells in a CD36- independent manner [35].
TSP-1 also indirectly influences angiogenesis through the
activation of TGF-b. In fact, TSP-1 is the only member of the
thrombospondin family that can activate TGF-b [36]. Even if
the precise mechanism underlying the activation of TGF-b by
TSP-1 is not fully understood, it seems that the amino acid
sequence RFK between the first and second TSRs of TSP-1 is
essential [37]. Of considerable importance is the transcriptional
regulation of tsp-1, Donoviel et al. found that the tsp-1 promoter
region and the 5¢-flanking region between -234 and + 750 are
important for basal transcriptional activity [38]. In this region
are localized several putative binding sites for known transcrip-
tional factors, including early growth response 1 (Egr-1) [39]
and specificity protein 1 (Sp-1) [40] sites. Huang et al. demon-
strated that Egr-1 expression increases the Sp-1 activation of
non-overlapping Sp-1 + Egr-1 sites, but inhibits the Sp-1 activity
when the sites are overlapping by competing with Sp-1 for the
binding site. In addition, Sp-1 is a strong inducer of Egr-1 sug-
gesting a mechanism by which Sp-1 facilitates the inhibition of
its own transactivating potential by induction of Egr-1. This
‘facilitated inhibition’ of Sp-1 transactivation activity by Egr-
1 could be a common mechanism for the regulation of a wide
range of growth-related genes [41].
In addition, TSP-1 expression seems to be regulated also by
miRNAs. In fact, a downregulation of c-myc increases the sta-
bility of TSP-1 mRNA through the decreased expression of
miR-17-92 cluster after treatment with 5-fluorouracil
(5-FU) [42]. MiR-17 ~ 92 cluster members, namely miR-18a
and miR-19, are involved in downregulating TSP-1 mRNA
and protein levels [43]. A direct regulator of TSP-1 expression
in colon epithelium-derived cell lines is miR-194 [44].
As a consequence, a widely employed approach in miRNA
loss-of-function studies is to use chemically modified anti-
sense oligonucleotides, termed antagomiRs, which sequester
the mature miRNA in competition with cellular target
mRNAs leading to functional inhibition of the miRNA and
derepression of the direct targets [45]. A deregulated expression
of miR-9, miR-31 and miR-182 during carcinogenesis plays a
significant role in the development of colon cancer by pro-
moting proliferation and tumor cell survival [46]. Interestingly,
the miR-182 gene, a component of the miRNA cluster
miR-183-96-182 located in the 7q32 genomic region, was
found amplified in 26% of primary tumors and 30% of liver
metastases, suggesting that miR-182 stimulates CRC progres-
sion by increasing the cell survival. Given that the liver is the
most common target organ for metastases of CRC and the
small oligonucleotides tend to accumulate in the liver for
clearance [47], anti-miR-182 therapy may have a potential in
the treatment of metastatic colon cancer.
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Since bio-informatic analyses reveal that TSP-1 mRNA is a
predictive target of miR-182 and that, in colon tumor sam-
ples, miR-182 is highly expressed with respect to normal
specimens [48], the aim of this study is to understand if the
silencing of miR-182 affects TSP-1 expression regulation in
human colon cancer cell lines. Because it is known that
miRNAs have pleiotropic effects, we focused our attention
on Egr-1 and Sp-1, predictive targets of miR-96/182/183
cluster, to establish if the effects of anti-miR-182 are mediated
by these transcriptional factors.
2. Materials and methods
2.1 Cell cultures
Three human colon cancer cell lines have been used: HT-29
(ATCC, Catalog No. HTB-38), Caco-2 (ECACC, Catalog
No. 86010202) and HCT-116 (ECACC, Catalog No.
91091005). HT-29 and HCT-116 were routinely grown in
Gibco Mc-Coy’s (Invitrogen, Carlsbad, CA, USA). Caco-
2 cell line were grown in Gibco DMEM:F-12 (L-glutamine
(+), 15 mM HEPES (+) NEAA (+), Invitrogen).
All media were supplemented with 10% fetal bovine serum
(FBS), 100 U/ml penicillin and 50 mg/ml streptomycin. Cells
were incubated at 37C in a humidified 5% CO2 atmosphere.
2.2 miRNA target prediction
The miRNA targets predicted by computer-aided algorithms
were obtained from DIANA micro-T (http://diana.cslab.ece.
ntua.gr/), miRBD (http://mirdb.org/miRDB/) and microRNA.
org (http://www.microrna.org/microrna/home.do).
2.3 Luciferase activity assay
The human tsp-1 3¢-UTR (untranslated region) target site was
amplified by polymerase chain reaction (PCR) and cloned
downstream of the luciferase gene in pMIR-REPORT
luciferase vector (Ambion, Austin, TX, USA). This construct,
named pMIR-TSP-1, was used for transfection in HT-29 and
HCT-116 cell lines. Colon cancer cells were cultured in
24-well plates and each transfected with 0.1 µg of either
pMIR-TSP-1 or pMIR-REPORT together with 0.01 µg of
pRL-TK vector (Promega) containing Renilla luciferase and
30 pmol of miR-182 (pre-miR-182) or negative control
(Ambion) according to manufacturer’s protocol. Transfection
was done using LipofectAMINE 2000 and Opti-MEM I
reduced serum medium (Life Technologies, Carlsbad, CA,
USA) in a final volume of 0.6 ml. Twenty-four hours after trans-
fection, firefly andRenilla luciferase activity weremeasured using
the Dual-Luciferase Reporter Assay (Promega). Each transfec-
tion was repeated twice in triplicate.Normalized data were calcu-
lated as the quotient of Renilla/firefly luciferase activities.
2.4 Anti-miRNAs transfections
Transfections were performed with anti-miR-182 (Ambion).
HT-29 and HCT-116 cells were seeded at 5  105 in
60 mm culture dish. After 24 h (40 -- 50% confluence), the
cells were transfected with anti-miR-182 (100 nM) using siPort
Neo Fx transfection agent (Ambion), according to manufac-
turer’s instructions. The mixture was transfected into all colon
cancer cell lines for 24 h in conditioned medium. Non-
specific anti-miR (Ambion) was used as negative control
together with mock control. The success of transfection was
confirmed by quantitative real-time PCR (qRT-PCR).
2.5 Quantitative real-time PCR to determine the
expression of miRNAs and TSP-1
Total cellular RNA and miRNAs were isolated using the
miRNeasy Mini Kit (Qiagen Inc., Valencia, CA, USA) and
quantified through RNA 6000 Nano Assay (Agilent Technol-
ogies, Palo Alto, CA, USA), and, using 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA), we evaluated
the integrity. For TSP-1 mRNA detection, 2 µg of total
RNA were reverse transcribed using the High Capacity
cDNA Archive kit (Applied Biosystems, Foster City, CA,
USA), according to manufacturer’s instructions and 5 µl of
the RT products were used to amplify TSP-1 mRNA
sequence using the Hs00962914-m1 TSP-1 TaqMan gene
expression assay (Applied Biosystems). Ten nanograms of
total RNA were reverse transcribed using Taqman MicroRNA
Reverse Transcription Kit (Applied Biosystems). The
obtained cDNA was amplified using Taqman hsa-
miR-182 MicroRNA assay (Applied Biosystems). The reac-
tions were incubated in a 96-well plate at 95C for 10 min
followed by 40 cycles of 95C for 15 s and 60C for 1 min.
The quantitative PCR was performed on an Applied Biosys-
tems 7900HT fast RT-PCR system, and data were collected
and analyzed using ABI SDS version 2.3. To normalize
qRT-PCR reactions, parallel reactions were run on each
sample for RNU6B snRNA or cyclophilin A. Changes in
the target mRNA content were determined using the compar-
ative CT method to calculate changes in CT, and ultimately
fold and percent change. An average CT value for each
RNA was obtained for replicate reactions.
2.6 Immunofluorescence
A total of 5 104 HT-29 and HCT-116 were plated in 4-well
Labtek II chamber slides (Nunc, Rockester, NY, USA). After
24 h, the cells were transfected with anti-miR-182 (100 nM)
for 48 h. Then, the cells were extensively washed with phos-
phate buffered saline (PBS) and fixed for 20 min at 4C in
4% paraformaldehyde. Next, the cells were permeabilized
with 0.2% Triton X-100 for 20 min, and unspecific binding
was blocked in 7.5% bovine serum albumin (BSA) fraction
V for 1 h at room temperature. Egr-1 expression was detected
using anti-Egr-1 (S-25) mouse monoclonal IgG (1:50; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) or anti-
SP-1 (H-225) rabbit polyclonal IgG (1:100; Santa Cruz Bio-
technology) and fluorescein isothiocyanate (FITC)-conjugated
goat anti-mouse IgG (1:1000; Santa Cruz Biotechnology) or
Alexa Fluor 488-conjugated goat anti-rabbit IgG (1:1000,
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells
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Molecular Probes; Invitrogen). In control experiments, primary
antibodies (Abs) were replaced by non-immune serum. The
slides were covered with Vectashield mounting medium con-
taining DAPI (Vector Laboratories, Burlingame, CA, USA)
to allow visualization of cell nuclei. The abundance of nuclear
Egr-1 and Sp-1 was assessed using Axioscope-40 microscope
and Zeiss axiovision LE software (Carl Zeiss, Jena, Germany).
2.7 TSP-1 detection by ELISA
A total of 5  105 HT-29 and HCT-116 cells were
transfected with anti-miR-182, as described before. After
treatment, conditioned medium was collected to measure
secreted TSP-1 expression levels using HumanQuantikine
ELISA Kits (R&D Systems, Minneapolis, MN, USA) follow-
ing manufacturer’s instructions. All points were done in trip-
licate and the experiments were repeated three times. All
TSP-1 concentrations were within the range of standard
curve. Linear regression analysis was performed to create the
standard curve. The range of curve standards was 7.81,
15.6, 31.3, 62.5, 125, 250, 500 pg/ml.
2.8 Western blotting
The cells, after transfection with anti-miR-182, were lysed to
obtain total proteins using Complete Lysis-M Reagent
(Roche, Mannheim, Germany) or cytoplasmic and nuclear
protein fractions using NE-PER Nuclear and Cytoplasmic
Extraction Reagents (Pierce Biotechnology Inc., Rockford,
IL, USA). The protein expression was analyzed in 120 µg of
total protein lysates and 80 -- 50 µg of cytoplasmic and
nuclear protein fractions. The following Abs were used for
western blotting (WB): anti-TSP-1 (3F357) mouse monoclo-
nal IgG1 (1:1000; Santa Cruz Biotechnology), anti-Egr-1
(S-25) mouse monoclonal IgG (1:500; Santa Cruz Biotech-
nology), anti-SP-1 (H-225) rabbit polyclonal IgG (1:1000;
Santa Cruz Biotechnology), anti-GAPDH (6C5) mouse
monoclonal Ab (1:1000; Santa Cruz Biotechnology), anti-
C23 (MS-3) mouse monoclonal Ab (1:1000; Santa Cruz
Biotechnology). The proteins were separated on an 8% poly-
acrylamide gel under denaturing conditions and transferred
by electrophoresis to a nitrocellulose membrane. Non-
specific binding was blocked by soaking membranes in 1X
TBS and 5% powered milk for at least 30 min at room tem-
perature. After the membrane was washed three times with
TBS and incubated with the following peroxidase (HRP)-
conjugated secondary Ab: goat anti-mouse IgG (sc-2005)
and goat anti-rabbit IgG (sc-2004) (Santa Cruz Biotechnol-
ogy) diluted 1:1000. The specific signal was detected with
ECL-WB substrate (Pierce Biotechnology Inc.).
2.9 Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed
using the Chromatin Immunoprecipitation Assay kit
(Upstate, Temecula, CA, USA), according to manufacturer’s
instructions. HT-29 and HCT-116 cells were transfected
with 100 nM anti-miR-182 for 48 h, or left untreated.
Next, the cells were cross-linked with 1% formaldehyde and
chromatin was collected and sonicated. Soluble chromatin
was immunoprecipitated with the following Abs: 5 µg anti-
Egr-1 (S-25) mouse monoclonal Ab (Santa Cruz Biotechnol-
ogy) or 5 µg anti-SP-1 (H-225) rabbit polyclonal IgG Ab
(Santa Cruz Biotechnology). DNA--protein immune com-
plexes were eluted, reverse cross-linked and DNA was
extracted with phenol/chloroform and precipitated. The pres-
ence of the TSP-1 promoter domain containing consensus
sequence for Egr-1 in immunoprecipitated DNA was identi-
fied first by conventional PCR using the following primers:
TSP-1 (region -482 to +162) forward 5¢-AACGAATGGC
TCTCTTGGTG-3¢, reverse 5¢-GGGCGACTTACCTGTG
TGTA-3¢ then by qRT-PCR.
qRT-PCR of DNA obtained from ChIP was performed
using SYBR Green I (Applied Biosystems). The same primers
amplify the promoter region containing Sp-1 consensus
sequences. The PCR conditions for the tsp-1 promoter region
were: 40 cycles at 1 min, 30 s at 95C, 30 s at 60C, 1 min at
72C. In control samples, the primary Abs were replaced with
non-immune rabbit IgG. To normalize qRT-PCR reactions,
chromatin inputs were used as control and were run on each
sample. Changes in the content relative to input were deter-
mined using a comparative CT method (ABI User Bulletin
no. 2). An average CT value for each sample was obtained
for triplicate reactions.
2.10 Statistical analysis
The correlations were studied by Student’s t-test. p-Values <
0.05 were considered statistically significant.
3. Results
3.1 miR-182 overexpression and
TSP-1 downregulation in HT-29 and HCT-116 colon
cancer cell lines
The miR-182 gene, a component of the miRNA cluster
miR-96/182/183 located in the 7q32 genomic region, was
found amplified in primary tumors and liver metastases, sug-
gesting that miR-182 stimulates CRC progression [48]. Given
that the liver is the most common target organ for metastases
of CRC [49], anti-miR-182 therapy may have a potential in
the treatment of metastatic colon cancer. Recently, the effi-
cient downregulation of miR-182 has been demonstrated to
decrease melanoma liver metastasis and tumor burden in
mice [50]. Preliminary evaluations were performed to assess
miR-182 and TSP-1 mRNA expression levels in HCT and
HT-29 cells, using Caco-2 as control, by qRT-PCR. We
decided to use Caco-2 cells, because it has been shown that
these cells spontaneously differentiate in culture and form a
polarized monolayer similar to that of the small intestine [51].
We observed that miR-182 was overexpressed by threefold in
HT-29 and by 2.1-fold in HCT-116 cells in respect to Caco-
2 cell line (Figure 1A). Then, we evaluated TSP-1 mRNA
V. Amodeo et al.
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expression levels in the same cells. Data showed that
TSP-1 mRNA levels were downregulated by 80% and by
95% in HT-29 and HCT-116 cells, respectively, with respect
to Caco-2 (Figure 1B). These first results indicate the inverse
correlation of the expression levels of TSP-1 and miR-182
in the in vitro model that we proposed as in literature
reported [52,48]. Then, hypothesizing the possible role of
miR-182 in TSP-1 regulation, we investigated the putative
angiogenetic role of miR-182 evaluating the consequence of
transient silencing of this miRNA on TSP-1 expression in
colorectal cancer cells. Relative expression data obtained after
transfection of anti-miR-182 in HT-29 and HCT-116
indicated an efficiency of silencing of miR-182 by 80 and
82%, respectively (Figure 1C).
3.2 Effects of anti-miR-182 on TSP-1 expression
TSP-1 expression levels are inversely correlated with tumor
vascularity; in fact, microvessel density is significantly higher
in TSP-1-negative colorectal tumors. Furthermore, it has
been shown that patients with TSP-1-negative tumors have
a significantly worse prognosis than those with TSP-1-positive
tumors.
TSP-1 may be useful for predicting recurrence in patients
with colon cancer because the frequency of hepatic recurrence
is significantly higher in patients with VEGF-positive and
TSP-1-negative colorectal tumors [53] in comparison with
those TSP-1-positives [52].
The fact that TSP-1 is a potent endogenous inhibitor of
angiogenesis and is often downregulated in tumor tissue lays
the basis to explore therapeutic applications of TSP-1. These
efforts fall into two basic approaches: the identification of
strategies to upregulate endogenous TSP-1, and the delivery
of recombinant TSRs or synthetic peptides that contain
sequences from the TSRs [54], though in theory a reasonable
approach must be balanced by the possible expected effects
of systemic loss of pro-flow signals from NO and VEGF.
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Figure 1. miR-182 and TSP-1 expression in colon cancer cell lines. A. miR-182 is upregulated in HT-29 and HCT-116 cancer cell
lines. The miR-182 expression level was studied with qRT-PCR. We used RUN6B as endogenous control. The graphs represent
respectively the fold abundance of miR-182 relative to Caco-2 colon cancer cell line – SD. B. TSP-1 mRNA is downregulated in
HT-29 and HCT-116 cancer cell lines. The abundance of TSP-1 mRNA was studied with qRT-PCR. To normalize TSP-1 qRT-
PCR reactions, parallel reactions were run on each sample for cyclophilin A (PPIA). The graphs represent respectively the
reduction of TSP-1 mRNA relative to Caco-2 colon cancer cell line – SD. C.miR-182 is downregulated by 20% in HT-29 and 18%
HCT-116 after transient transfection with anti-miR-182. The graphs represent respectively the fold abundance of
miR-182 relative to control and negative control; – SD.
A. *p < 0.05. B. *p < 0.05. C. *p < 0.05, zp < 0.01.
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Here, to investigate the effect of miR-182 on the expression
levels of TSP-1, we evaluated the effect of transient silencing
miR-182 to restore TSP-1 expression in colon cancer cell
lines. Anti-miR-182 is a synthetic single-stranded oligonucle-
otide chemically modified designed to specifically bind and to
inhibit the endogenous miR-182. Following miR-182
silencing, we observed that TSP-1 mRNA increased by 2.4-
and 3.1-fold in HT-29 and HCT-116, respectively, relative
to untransfected and negative control cells (Figure 2A). We
also evaluated intracellular and secreted TSP-1 protein levels.
WB results, obtained from total cellular lysates, indicated that
intracellular TSP-1 protein levels increased in transfected
HT-29 and in HCT-116 cells by 1.8- and 3.6-fold,
respectively (Figure 2B).
The effects of anti-miR-182 on the secreted TSP-1 protein
mirrored the above findings. As expected, after transfection,
we analyzed the amount of secreted TSP-1 that showed fold
changes of 2.2 and 2.8 in HT-29 and HCT-116 cells, respec-
tively (Figure 2C). According to these results, miR-182 affects
TSP-1 protein levels but could have influence on
transcriptional regulation of tsp-1 expression.
3.3 miR-182 directly targets TSP-1
Identification of miRNA-regulated gene targets is a necessary
step to understand miRNA functions. The online target predic-
tion databases indicate one highly conserved putative target site
in the 3¢UTR of tsp-1 for the seed sequence of miR-182 located
at 1959--1965 nt (Figure 3A). To investigate whether a direct
interaction is involved between miR-182 and its target
TSP-1, we performed luciferase reporter assays. We generated
a luciferase construct that contains the potential binding
sequence of TSP-1 3¢UTR to miR-182, then HT-29 and
HCT-116 cells were transfected with this construct and lucifer-
ase activity was measured 24 h after transfection.
Luciferase activity was significantly decreased by 46 and
39% fold in HT-29 and HCT-116 transfected with pMIR-
TSP-1 compared with cells transfected with pMIR-REPORT,
the empty vector, suggesting translational repression of
TSP-1 mRNA by overexpressed endogenous miR-182. In
addition, miR-182 precursor significantly decreased luciferase
reporter by 75 and 65% in HT-29 and HCT-116, respec-
tively. By contrast, anti-miR-182 markedly increased TSP-1
3¢UTR-associated luciferase reporter translation by 1.89-
and 1.92-fold in HT-29 and HCT-116 cells with respect to
co-transfected cells with negative control (Figure 3B).
3.4 Silencing of miR-182 slightly affects Egr-1 and
Sp-1 protein levels in HCT-116 and HT-29 cells
The 5¢-flanking region between -234 and + 750 on tsp-1 pro-
moter region presents binding sites for Egr-1 and Sp-1 tran-
scriptional factor. These transcriptional factors can compete
to bind the same GC-rich sites.
Since Egr-1 and Sp-1 are predictive targets of
miR-96/182/183 cluster [55], we investigated the molecular
mechanism by which anti-miR-182 could determine
TSP-1 upregulated expression in colon cancer cells, as reported
previously. For this reason, we evaluated if anti-
miR-182 influences Egr-1 and Sp-1 expression in the in vitro
model that we decided to study. WB analysis did not reveal
significant variation of Egr-1 total protein levels, band analysis
in fact indicated just an upregulation of 22% after transfection
with anti-miR-182 in HCT-116 cell lines. In parallel, Sp-1
was slightly increased, only 20%, in HT-29 cells transfected
with anti-miR-182 with respect to untransfected cells. More-
over, we did not find any variation of Egr-1 and Sp-1 in
HT-29 and HCT-116, respectively with anti-miR-182 com-
pared with control and negative control (Figure 4). These
results reveal that the silencing of miR-182 not affects signifi-
cantly the protein expression of these transcriptional factors
involved in activation of tsp-1 expression.
3.5 Anti-miR-182 modulates Egr-1 and Sp-
1 expression and nuclear translocation in colon can-
cer cells
At the light of the data described above, we hypothesized that
miR-182 could affect cytoplasmatic and nuclear localization
of Egr-1 and Sp-1, for this reason we studied the effect of
anti-miR-182 on Egr-1 and Sp-1 expression on fractionated
lysates after transfection with anti-miR-182. We found both
cytosolic and nuclear accumulation of Egr-1 in transfected
HCT-116 with respect to untransfected cells. Moreover, we
observed that anti-miR-182 affects nuclear accumulation of
Egr-1 in HT-29 cells. In fact, WB data evidenced a reduction
of cytosolic fraction and an increase of nuclear translocation
of Egr-1, at the same time, in HT-29 transfected with anti-
miR-182. Probably, miR-182 has a regulatory role in this
event that here we did not investigate (Figure 5A). Further-
more, WB analysis on fractionated protein extracts revealed
that nuclear abundance of Sp-1 slightly increased in
HT-29 cells transfected with anti-miR-182 with respect to
untransfected and negative control cells, whereas anti-
miR-182 seems to not affect Sp-1 nuclear accumulation in
HCT-116 cell line (Figure 5A).
Changes in nuclear and cytoplasmic accumulation were
confirmed by immunofluorescence analysis, which revealed
that Egr-1 levels were considerably upregulated in both cyto-
plasm and nucleus of HCT-116 transfected with anti-
miR-182 compared with untransfected cells (Figure 5B).
Moreover, immunofluorescence analysis shows that transfec-
tion with anti-miR-182 determined increased levels of nuclear
Sp-1 in HT-29 and not causes any variation on Sp-1 levels in
HCT-116 (Figure 5C).
3.6 Egr-1 and Sp-1 binding to TSP-1 promoter is
influenced by anti-miR-182 in HT-29 and
HCT-116 cells
Next, we assessed whether these factors bind specific consen-
sus sequences into tsp-1 promoter (from -482 to + 162) after
V. Amodeo et al.
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transfection with anti-miR-182. Using ChIP assay, we found
that the Egr-1 binding to tsp-1 promoter significantly
increased by 3.5-fold in HCT-116 cells transfected with
anti-miR-182 compared with untransfected cells. Although
our data showed that anti-miR-182 induces the nuclear accu-
mulation of Egr-1 in HT-29 cells, as before describe, we did
not observe the Egr-1 recruitment on the consensus sequence
into tsp-1 promoter in this cell line (Figure 6A). Since Sp-
1 binds to two GC boxes lying between -267 and -71 at the
5¢-flanking region of the tsp-1 gene [40], we assessed the
recruitment of Sp-1 on tsp-1 promoter sequence after transfec-
tion with anti-miR-182. Data indicated that Sp-1 bound by
1.7-fold to tsp-1 promoter sequence in transfected
HT-29 with respect to control cells. However, Sp-1 did not
show significant binding to tsp-1 consensus region both in
transfected with anti-miR-182 and untransfected
HCT-116 cells (Figure 6A). In addition, we validated these
results by RT-PCR and our findings showed that Egr-1 is
R
el
at
iv
e 
TS
P-
1 
m
RN
A 
le
v
el
0
0.5
1
1.5
2
2.5
3
A.
R
el
at
iv
e 
TS
P-
1 
ab
u
n
da
nc
e
0
0.5
1
1.5
2
B.
R
el
at
iv
e 
TS
P-
1 
ab
u
n
da
nc
e
0
0.5
1
1.5
2
2.5
3
3.5
R
el
at
iv
e 
se
cr
et
ed
 T
SP
-1
 le
v
el
 (p
g/m
L)
0
0.5
1
1.5
2
2.5
3
3.5
4
C.
∗
∗
HT
29
 Co
ntr
.
HT
29
 Ne
g. C
on
tr.
HT
29
 an
tim
iR-
18
2
HT
29
 Co
ntr
.
TSP-1
GAPDH
HT
29
 Ne
g. C
on
tr.
HT
29
 an
ti-m
iR-
18
2
HT
11
6 a
nti
mi
R-
18
2
HT
11
6 N
eg
. C
on
tr.
HT
11
6 C
on
tr.
HT
29
 Co
ntr
.
HT
29
 Ne
g. C
on
tr.
HT
29
 an
tim
iR-
18
2
HT
11
6 a
nti
mi
R-
18
2
HT
11
6 N
eg
. C
on
tr.
HT
11
6 C
on
tr.
TSP-1
GAPDH
HT
11
6 a
nti
-m
iR-
18
2
HT
11
6 N
eg
. C
on
tr.
HT
11
6 C
on
tr.
Figure 2. Anti-miR-182 influences TSP-1 expression. A. The expression of TSP-1 mRNA was studied after HT-29 and
HCT-116 transfection with synthetic oligonucleotides targeting miR-182 (anti-miR-182) or with negative control anti-
miR molecules, as described in Section 2. The graph indicates that TSP-1 mRNA levels increase in transfected cells relative to
negative control. p < 0.05 control vs anti-miR-182. B. The abundance of TSP-1 total protein was determined by WB in 120 µg of
total proteins, as described in Section 2. The images indicate the increase of TSP-1 protein levels relative to untransfected cells.
C. The concentration of secreted TSP-1 was measured by ELISA in cells transfected with anti-miR-182 or with negative control
anti-miR. The concentrations represent pg TSP-1/ml conditioned medium from 5  105 cells.
*p < 0.05
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Figure 4. Effects of anti-miR-182 on Egr-1 and Sp-1 protein expression. HCT-116 and HT-29 cells were transfected with anti-
miR-182 as previously described. Egr-1 and Sp-1 levels were assessed by WB using specific Abs, as described in Section 2.
*p < 0.05
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recruited on tsp-1 promoter in HCT-116 transfected cells and
Sp-1 in HT-29 with anti-miR-182 promoting assembly of a
functional transcription complex in both cases (Figure 6B).
4. Discussion
The anti-angiogenic effects of TSP-1 is mediated also by the
ligation of CD47, inhibiting VEGFR2 activation [56,32],
decreasing migration of endothelial cells [35] and adenylate
cyclase activation [57].
Given the importance of TSP-mediated effects on angio-
genesis, apoptosis and extracellular matrix composition, con-
siderable interest has been shown in using this protein as a
clinical therapeutic. Generally, two approaches to increasing
TSP-mediated inhibition of angiogenesis have been explored
in the context of neoplasia: administration of chemotherapies
based on recombinant TSP or a TSP-derived peptide, includ-
ing the TSRs of TSP-1 and TSP-2 and upregulation or poten-
tiation of the effects of endogenous TSPs. However, in
contexts in which tissue ischemia limits recovery, it may be
beneficial to suppress TSP expression in order to promote
angiogenesis, in fact interrupting the TSP-1--CD47
interaction is highly beneficial in ischemia, ischemia-
reperfusion injury, hypoxia and high-dose radiation settings
suggesting a priority signal in the cardiovascular system [58].
Aberrant expression of miRNAs is correlated with the
development and progression of tumors, and the reversal of
their expression has been shown to modulate the cancer phe-
notype, suggesting the potential of miRNAs as targets for
anti-cancer drugs. Considering that several miRNAs have
been found to regulate the process of cancer metastasis inde-
pendent of primary tumorigenesis [59], in this study, we
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Figure 6. Egr-1 and Sp-1 binding to TSP-1 promoter is modulated by miR-182 in HT-29 and HCT-116 cells. The binding of Egr-
1 and Sp-1 to the proximal TSP-1 promoter region (-482/+ 162) was tested by ChIP (A) and qRT-PCR (B) in HT-29 and
HCT-116 cells transfected with anti-miR-182. Increased Egr-1 binding on TSP-1 promoter sequence in transfected HCT-116 cells;
Egr-1 is not recruited after transfection with anti-miR-182 in HT-29 cells. Sp-1 increased binding on its consensus motif in
HT-29 cells induced by anti-miR-182; Sp-1 is not recruited in HCT-116 cells. ChIP experiments were performed as described in
Section 2.
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describe the effects of anti-miR-182 in the expression of
TSP-1 in colon cancer cell lines. Our data indicated an inverse
correlation in expression that induced us to investigate whether
miR-182 could regulate TSP-1 expression. For this purpose,
we silenced miR-182 using a synthetic oligonucleotide, anti-
miR-182, that targets the mature forms of miR-182 and
thereby contrasts their expression and function in HT-29
and HCT-116 cells. We found that the transfection with
anti-miR-182 increased TSP-1 intracellular and secreted pro-
tein expression levels. By luciferase assay, we validated that
TSP-1 is a target of miR-182, in fact, this miRNA directly
interacts with 3¢-UTR of TSP-1 and blocks TSP-1 translation.
Moreover, we found that anti-miR-182 determined
increased expression levels of mRNA TSP-1, supposing that
anti-miR-182 could affect TSP-1 expression by affecting tran-
scriptional factors expression that bind tsp-1 gene promoter,
we focused our attention on Egr-1 and Sp-1. Both are
Cys2-His2-type zinc-finger transcription factors and binds to
GC-rich, cis-acting promoter elements, in fact, overlapping
Sp-1 and Egr-1 sites are frequent [41].
Our results, obtained after transfection, indicated that anti-
miR-182 influences nuclear accumulation both Egr-1 and
Sp-1 in HT-29 cells, whereas anti-miR-182 affects nuclear
translocation of Egr-1 only in HCT-116 cells. Subsequent
ChIP analyses revealed an increased Sp-1 binding into proxi-
mal promoter region of tsp-1 gene as a consequence of its
increased nuclear accumulation in HT-29. Conversely, we
did not observe Egr-1 recruitment despite its major nuclear
amount. Moreover, we found an Egr-1 increased loading on
tsp-1 promoter in HCT-116 cells transfected with anti-
miR-182 and we did not observe the recruitment of Sp-1,
which not shows any variation between cytosolic and nuclear
levels. Sp-1 increases the amount of Egr-1, which then
becomes a potent competitor of Sp-1 for binding to consensus
sequence [41]. Since Egr-1 inhibits the transactivation of Sp-
1 on overlapping Sp-1/Egr-1 binding sites and Sp-1 activity
could be augmented by Egr-1 at non-overlapping sites in
the Egr-1 gene promoter, we hypothesized a possible regula-
tory mechanism in which anti-miR-182 increased the nuclear
amount of both Egr-1 and Sp-1 in HT-29 cells. In this con-
text, probably there is not a competition between Egr-1 and
Sp-1 to load consensus sequence because Sp-1 binds non-
overlapping sites. Reduced levels of miR-182 make Sp-1 the
major transcriptional factor implicated in the TSP-1 expres-
sion without the involvement of Egr-1 in HT-29 cells. On
the contrary, in HCT-116 cell line, the molecular mechanism
by which anti-miR-182 could indirectly modulate TSP-1 is
based on the physical displacement of Sp-1 on DNA by
Egr-1. In this work, we showed that anti-miR-182 mediates
suppression of angiogenic activity through the induction of
the TSP-1 angiogenesis inhibitor by direct targeting, regula-
tion transcriptional events on tsp-1 promoter. The fact that
TSP-1 is a potent endogenous inhibitor of angiogenesis
prompted several groups to explore therapeutic applications
of TSP-1, endeavoring to identify strategies to increase endog-
enous TSP-1 and the delivery of recombinant TSP-1 repeats
(TSRs) or synthetic peptides that contain sequences
from TSRs.
Research undertaken to identify and optimize short bioactive
peptides derived from the two TSP-1 anti-angiogenic domains,
which bind CD47 and CD36 cell surface receptors [60].
Future investigations are expected to reveal the molecular
basis for the different effects of TSP-1 on tumorigenesis in
several tumor types and to describe the molecular pathways
for the regulation of TSP-1 by multiple tumor suppressor
genes and oncogenes. In particular, we focused our attention
on miRNAs, small regulatory non-coding RNAs, which regu-
late mRNA function and which play a crucial role in cancer,
acting as oncogenes or tumor suppressor genes. miRNA ther-
apeutics appears as a novel field in which miRNA activity is
the major target of the intervention.
5. Conclusion
In this work, we showed the potential regulatory role of anti-
miR-182 on TSP-1 expression in colon cancer. In the light of
these results that remark the involvement of miRNAs in can-
cer pathogenesis, miRNAs could become new targets for the
development of novel therapeutic strategies in order to restore
physiological gene expression levels and to modulate
indirectly the expression of their targets. Moreover, the dis-
covery of more miRNA targets will be useful to better define
the cancer cells signaling and to identify new and more
effective drugs.
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